104.09
0.74%
-0.78
After Hours:
103.99
-0.10
-0.10%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is currently priced at $104.09, with a 24-hour trading volume of 6.42M.
It has seen a -0.74% decreased in the last 24 hours and a -1.71% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $104.7 pivot point. If it approaches the $103.7 support level, significant changes may occur.
Previous Close:
$104.87
Open:
$104.41
24h Volume:
6.42M
Market Cap:
$181.08B
Revenue:
$40.33B
Net Income/Loss:
$5.63B
P/E Ratio:
35.40
EPS:
2.94
Net Cash Flow:
$4.92B
1W Performance:
-0.62%
1M Performance:
-1.71%
6M Performance:
+4.56%
1Y Performance:
-4.35%
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
224-667-6100
Address
100 Abbott Park Road, Abbott Park, IL
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-20-23 | Reiterated | Barclays | Overweight |
Apr-20-23 | Reiterated | Bernstein | Outperform |
Apr-20-23 | Reiterated | JP Morgan | Overweight |
Apr-20-23 | Reiterated | Raymond James | Outperform |
Apr-20-23 | Reiterated | UBS | Buy |
Apr-20-23 | Reiterated | Wolfe Research | Underperform |
Mar-29-23 | Initiated | UBS | Buy |
Oct-26-22 | Initiated | Mizuho | Neutral |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Hold |
Jul-06-22 | Initiated | Wolfe Research | Underperform |
Mar-02-22 | Resumed | BofA Securities | Buy |
Jan-27-22 | Reiterated | Credit Suisse | Outperform |
Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
Jan-27-22 | Reiterated | Raymond James | Outperform |
Jan-27-22 | Reiterated | UBS | Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
Oct-14-21 | Initiated | Redburn | Neutral |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Neutral |
Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
Sep-11-20 | Initiated | Wolfe Research | Outperform |
Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Neutral |
Feb-06-20 | Resumed | BTIG Research | Neutral |
Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
Jun-13-19 | Reiterated | BofA/Merrill | Buy |
Feb-07-19 | Reiterated | BofA/Merrill | Buy |
Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
Oct-16-18 | Initiated | Barclays | Overweight |
Jun-27-18 | Initiated | Bernstein | Outperform |
Jan-30-18 | Reiterated | Citigroup | Neutral |
Jan-25-18 | Reiterated | Stifel | Buy |
Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-03-18 | Initiated | Evercore ISI | Outperform |
Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
MarketWatch
Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Yahoo Finance
At 6.3% CAGR of U.S. Clinical Nutrition Market Expected to Expand at a Steady 2024-2031 | Abbott Laboratories, - EIN News
EIN News
Abbott reports more HeartMate LVAD problems - Mass Device
Mass Device
Abbott Laboratories stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
MarketWatch
Abbott reports more HeartMate LVAD problems - Mass Device
Mass Device
Abbott Laboratories Stock (ABT) Financials Data
Abbott Laboratories (ABT) Revenue 2024
ABT reported a revenue (TTM) of $40.33 billion for the quarter ending March 31, 2024, a -2.84% decline year-over-year.
Abbott Laboratories (ABT) Net Income 2024
ABT net income (TTM) was $5.63 billion for the quarter ending March 31, 2024, a -3.00% decrease year-over-year.
Abbott Laboratories (ABT) Cash Flow 2024
ABT recorded a free cash flow (TTM) of $4.92 billion for the quarter ending March 31, 2024, a -27.85% decrease year-over-year.
Abbott Laboratories (ABT) Earnings per Share 2024
ABT earnings per share (TTM) was $3.21 for the quarter ending March 31, 2024, a -2.43% decline year-over-year.
Abbott Laboratories Stock (ABT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Funck, Jr. Robert E. | EXECUTIVE VICE PRESIDENT |
May 10 '24 |
Option Exercise |
47.00 |
10,097 |
474,559 |
221,438 |
Funck, Jr. Robert E. | EXECUTIVE VICE PRESIDENT |
May 10 '24 |
Sale |
104.57 |
10,097 |
1,055,819 |
211,341 |
Earnhardt Lisa D | EXECUTIVE VICE PRESIDENT |
May 07 '24 |
Sale |
106.25 |
22,852 |
2,428,119 |
61,462 |
Salvadori Daniel Gesua Sive | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
963 |
114,116 |
125,697 |
ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
853 |
101,080 |
184,806 |
Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
801 |
94,918 |
62,968 |
Earnhardt Lisa D | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
694 |
82,239 |
84,314 |
Moreland Mary K | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
676 |
80,106 |
91,260 |
MCCOY JOHN A. JR. | VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
472 |
55,932 |
18,760 |
Wainer Andrea F | EXECUTIVE VICE PRESIDENT |
Feb 23 '24 |
Option Exercise |
59.94 |
12,500 |
749,250 |
91,204 |
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Cap:
|
Volume (24h):